Skip to content
Peptide research

Selank

Also known as TP-7 · Selanc
Category
Brain & Cognition
Administration routes
Nasal
Regulatory status
Not FDA-approved

A synthetic, stabilized analog of the immune peptide tuftsin, used intranasally mainly for anxiety, focus, and immunity. Its anxiolytic and anti-inflammatory effects have the most support, but human trials are almost all Russian, small, and short (7 to 21 days). The FDA has flagged immunogenicity, with no pregnancy, lactation, or pediatric data. Not an approved US drug, and most supply outside Russia is unregulated research-grade material.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Selank is a synthetic seven-amino-acid peptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s. It is built on tuftsin, a natural immune-boosting fragment of human antibodies (IgG), with three extra amino acids added for stability. Selank was registered in Russia in 2009 for anxiety-related conditions; its 0.15% nasal drops are now available there without prescription. Ukrainian authorization was not verified. It provides anti-anxiety effects comparable to benzodiazepines (like Valium) but without the sedation, memory impairment, tolerance, or dependence those drugs cause. It is not FDA-approved, and no established US compounding pathway was identified.

How it works in the body

A synthetic analog of the immune peptide tuftsin with a Pro-Gly-Pro extension for stability. It modulates GABA-A receptors, increases BDNF expression, and influences serotonin metabolism in the brain. It also enhances IL-6 expression and other immune modulators, providing both anxiolytic and immune-boosting effects.

Research overview

Selank reduces anxiety through several brain mechanisms working in concert. It enhances GABA-A receptor activity (the same calming system targeted by benzodiazepines, but at a different binding site), modulates serotonin and dopamine signaling, and rapidly increases BDNF — a key protein that supports brain cell growth, learning, and memory. It also has anti-inflammatory effects, altering the expression of 34 inflammation-related genes in immune tissue. A 62-patient randomized trial reported anxiety relief comparable to medazepam. In a separate 20-patient study reported as a conference abstract, 40% were rapid responders, with anxiety scores falling from 20.3 to 7.0 within three days. Animal studies show it prevents stress-induced memory impairment by regulating BDNF in the hippocampus, and it alters expression of 45 of 77 genes involved in the brain's calming (GABAergic) system. The evidence base is moderate: strong preclinical data across multiple mechanisms with positive but limited human data, predominantly from Russian institutions. Large international trials and independent replication are still needed.

Who researches Selank?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching immune system support

    Studied for immune modulation, antiviral, or antimicrobial properties.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People exploring anxiety and stress management

    Researched for anxiolytic or stress-reducing properties.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data outside Russia.

  • Those with Severe hypotension

    Moderate

    Selank's anxiolytic effects may further lower blood pressure.

Safety & interactions

Do not use if

  • Severe hypotension

    Moderate

    Selank's anxiolytic effects may further lower blood pressure.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data outside Russia.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • Most clinical studies examine only 7-21 day treatment periods

    Moderate

    PMID 18454096 (14-day trial design); published Selank trial durations

  • FDA cited immunogenicity as a safety concern

    Moderate

    FDA interim 503A Category 2 bulks list rationale for Selank acetate (immunogenicity, peptide-related impurities, limited human safety data); FDA Sept 2024 removal of Selank acetate from Category 2 upon nominator withdrawal

  • Mild nasal or throat irritation (intranasal)

    Low

    peptides.org / clinical safety summaries; Russian trial tolerability data

  • Rare mild dizziness

    Low

    Clinician-reported side-effect summaries

  • No safety data in pregnancy, lactation, or children

    Moderate

    Absence of studies; standard peptide safety-labeling gap

  • Mostly research-grade outside Russia/Ukraine

    Moderate

    FDA non-approval status; peptide-related impurity concerns in compounding rationale

Interaction summary(5)

Rated by direction with this peptide

  • Benzodiazepines (diazepam, medazepam, phenazepam)

    SynergisticLow

    Selank potentiated the anxiolytic effect of diazepam in rat chronic-mild-stress models and augmented benzodiazepine effects in mice via the shared GABA-A/benzodiazepine site, so co-use may additively enhance anxiolysis (Selank itself is non-sedating). Direct human co-administration data are lacking; severity reflects the strong mechanistic and animal evidence base, not a demonstrated clinical event.

    Kasian et al. 2017, Behav Neurol doi:10.1155/2017/5091027 (Selank enhances diazepam in chronic mild stress, rats); combined benzodiazepine+Selank action, BALB/c mice

  • Alcohol / ethanol (withdrawal setting)

    ProtectiveTheoretical

    In rodent models Selank eliminated ethanol-withdrawal anxiety and prevented withdrawal-associated memory/attention impairment, suggesting a protective role during alcohol withdrawal; no human data, and acute co-intoxication effects are untested.

    PMID 24913576 (Selank in rat alcohol-withdrawal modeling); Bull Exp Biol Med 2019 (withdrawal memory protection)

  • Serotonergic agents (SSRIs/SNRIs)

    CautionTheoretical

    Selank alters serotonin turnover and reduces serotonin reuptake velocity in animal/synaptosomal models, so a theoretical additive serotonergic effect exists; no serotonin-syndrome or interaction signal has been reported in humans.

    Animal/in-vitro serotonin and SERT studies (Semenova, Narkevich)

  • Opioids / enkephalinase-dependent signaling

    CautionTheoretical

    By inhibiting enkephalin-degrading enzymes Selank prolongs endogenous opioid peptide activity in vitro, raising a mechanistic possibility of potentiated opioidergic tone; this has not been demonstrated in vivo or clinically.

    PMID 11443939 (Kost et al. 2001, enkephalin-degrading enzyme inhibition)

  • Immunomodulatory / immunosuppressive therapy

    CautionTheoretical

    As a tuftsin analog Selank modulates cytokine and inflammation-related gene expression (shown in patients and animals), so a theoretical interaction with immune-modulating drugs is plausible; direction and clinical relevance are unquantified.

    PMID 18577961 (Uchakina et al. 2008, immunomodulation in patients); Kolomin inflammation-gene studies

Known risks(6)

  • Limited long-term safety data

    Moderate (uncertainty)

    Most clinical studies examine 7-21 day treatment periods. No human studies have evaluated continuous Selank use beyond several weeks. Chronic safety, including effects on GABAergic system homeostasis, endocrine function, and immune regulation with prolonged use, remains uncharacterized. The short half-life (~25-30 minutes) necessitates multiple daily doses, increasing cumulative exposure concerns.

  • Potential immunogenicity

    Moderate

    The FDA cited immunogenicity as a safety concern when placing Selank on the Category 2 list — the possibility that the body could perceive the peptide as a threat and mount an immune response. While Selank is derived from the endogenous peptide tuftsin and clinical studies have not reported allergic or anaphylactic reactions, the immunogenicity risk with repeated dosing in diverse populations has not been thoroughly evaluated in large trials.

  • Nasal irritation and mild headache

    Low

    The most commonly reported side effects in clinical use. Mild nasal or throat irritation when administered as a nasal spray, and occasional mild headaches potentially related to neurotransmitter modulation. These are generally transient and resolve without intervention.

  • Mild dizziness

    Low

    Rare reports of mild dizziness, likely related to Selank's effects on GABAergic neurotransmission and blood pressure modulation. Generally self-limiting.

  • Pregnancy and lactation safety unknown

    High (contraindicated due to insufficient data)

    No safety data exists for Selank use during pregnancy, lactation, or in children. Given its immunomodulatory and neurotransmitter-modifying properties, experts advise against use in pregnant or breastfeeding women until safety data is available.

  • Research-grade purity concerns

    Moderate

    Outside of Russia and Ukraine, most Selank available is unregulated products sold online, with unvalidated purity, potency, and sterility. Contaminants, incorrect concentrations, or degraded peptide pose risks when used for self-administration. Pharmaceutical-grade Selank is effectively only available through Russian pharmacies.

Drug interactions(6)

  • Benzodiazepines (diazepam, phenazepam, medazepam)

    Selank can enhance the positive anxiolytic effects of benzodiazepines while potentially reducing their adverse effects. Kasian et al. 2017 showed the combination of Selank + diazepam was most effective at reducing anxiety under chronic stress. However, Vyunova et al. 2018 showed Selank can also block the modulatory activity of diazepam at GABA-A receptors, suggesting complex interactions at overlapping binding sites. Combined use should be monitored clinically.

  • SSRIs and serotonergic drugs (fluoxetine, sertraline, citalopram)

    Selank modulates serotonin metabolism and serotonergic neurotransmission. Concurrent use with SSRIs or other serotonergic drugs may produce additive or unpredictable effects on serotonin signaling. While no dangerous interactions have been documented, caution is advised and patients should inform their prescriber of concurrent serotonergic medication use.

  • Antipsychotics (olanzapine and others)

    Vyunova et al. 2018 demonstrated that Selank can block the modulatory activity of olanzapine at GABA-A receptors. This suggests potential pharmacodynamic interactions that could alter the efficacy or side effect profile of antipsychotic medications. Combined use requires careful clinical monitoring.

  • Dopaminergic drugs (L-DOPA, dopamine agonists)

    Selank influences dopaminergic neurotransmission and dopamine receptor expression. Concurrent use with dopaminergic medications may produce additive effects. Clinical significance is not well characterized but monitoring is prudent.

  • Immunomodulatory and immunosuppressant drugs

    Selank has documented immunomodulatory effects including alteration of Th1/Th2 cytokine balance, IL-6 modulation, and regulation of 34+ inflammation-related genes. These effects could theoretically interact with immunosuppressant or immunomodulatory medications (e.g., methotrexate, cyclosporine, biologics). Patients on immunomodulatory therapy should consult their physician before using Selank.

  • Other nootropic peptides (Semax, Noopept)

    Selank and other nootropic peptides, particularly Semax, modulate overlapping neurotransmitter systems. No adverse interactions have been documented, but the joint neuropharmacological effects are not fully characterized and clinical supervision is recommended.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
35
Human Studies
5

Selank's clinical evidence base is moderate but geographically concentrated. The primary human evidence comes from Russian clinical trials: an RCT in 62 GAD/neurasthenia patients showing anxiolytic efficacy comparable to medazepam without benzodiazepine side effects (Zozulia et al. 2008); a clinical evaluation in 20 GAD patients identifying rapid and slow responder subtypes with significant HARS score reductions (Syunyakov et al. 2012); and immunomodulatory effects documented in anxiety patients showing IL-6 suppression and Th1/Th2 rebalancing (Uchakina et al. 2008). Preclinical evidence is substantially more extensive, with well-designed studies demonstrating BDNF elevation, GABAergic gene modulation, anti-inflammatory cytokine regulation, neuroprotection against ethanol-induced cognitive impairment, and attenuation of opioid withdrawal. The major gaps are the absence of large international RCTs replicating the Russian clinical findings, no long-term safety studies beyond 14-21 day treatment courses, and no clinical trials specifically targeting aging or longevity outcomes.

Researched for(6)

Rated by confidence in the evidence

  • Anxiolytic effects comparable to benzodiazepines without their side effects

    Medium

    Small human trials found anxiety relief comparable to benzodiazepines, without sedation or dependence.

    PMID 18454096 (Zozulia et al., Zh Nevrol Psikhiatr 2008, Selank vs medazepam); comparative Selank-vs-phenazepam trial in anxiety disorders (Zh Nevrol Psikhiatr)

  • Neuroprotection and cognitive enhancement via BDNF elevation

    Low

    The cited rat study found preserved memory and prevention of an ethanol-induced BDNF increase; human cognitive benefit remains unestablished.

    Bull Exp Biol Med 2019, doi:10.1007/s10517-019-04588-9 (Selank/ethanol memory, BDNF in hippocampus & PFC)

  • Anti-inflammatory and immunomodulatory effects

    Medium

    A human study showed shifted cytokine levels; clinical anti-inflammatory benefit remains unproven.

    PMID 18577961 (Uchakina et al. 2008, immunomodulatory effects in patients with anxiety-asthenic disorders); Kolomin et al., inflammation-related gene expression in mouse spleen

  • GABAergic system stabilization and neurotransmitter regulation

    Low

    Animal gene-expression work supports possible GABAergic modulation; it does not establish binding at the benzodiazepine site.

    Front Pharmacol 2016, doi:10.3389/fphar.2016.00031 (GABAergic gene expression)

  • Stress resilience and anti-withdrawal effects

    Low

    Rodent studies reduced withdrawal anxiety and stress responses; no human trials yet.

    PMID 24913576 (Efficacy of Selank during withdrawal syndrome modeling in rats with stable alcoholic motivation)

  • Enkephalin system modulation and endogenous opioid regulation

    Low

    In test-tube human serum, Selank slowed enkephalin breakdown; body-wide effects remain unproven.

    PMID 11443939 (Kost et al. 2001, Semax and Selank inhibit enkephalin-degrading enzymes of human serum)

Benefits(6)

  • Anxiolytic effects comparable to benzodiazepines without their side effects

    Zozulia et al. 2008 (Zh Nevrol Psikhiatr, PMID 18454096) — RCT in 62 patients with GAD and neurasthenia: intranasal Selank showed anxiolytic efficacy comparable to medazepam, with additional antiasthenic and psychostimulant effects but without sedation, muscle relaxation, amnesia, tolerance, or withdrawal. Syunyakov et al. 2012 (European Psychiatry) — In 20 GAD patients, 40% were rapid responders with HARS scores dropping from 20.3 to 7.0 within 1-3 days. Vyunova et al. 2018 (Protein and Peptide Letters, PMID 30255741) — Selank acts as a positive allosteric modulator of GABA-A receptors, mechanistically distinct from benzodiazepines.

  • Preclinical memory protection associated with BDNF regulation

    Kolik et al. 2019 (Bull Exp Biol Med, PMID 31625062) — Selank (0.3 mg/kg/day for 7 days) prevented ethanol-induced memory and attention disturbances in aging rats and exerted a cognitive-stimulating effect in unexposed 9-month-old rats by regulating BDNF content in the hippocampus and prefrontal cortex. BDNF is a key neurotrophin for synaptic plasticity, learning, and memory that declines with age.

  • Anti-inflammatory and immunomodulatory effects

    Yasenyavskaya et al. 2021 (Curr Rev Clin Exp Pharmacol, PMID 32621722) — Selank (100 mcg/kg/day) significantly reduced IL-1beta, IL-6, TNF-alpha, and TGF-beta1 under chronic social stress in rats, restoring cytokine levels toward control values. Kolomin et al. 2011 (Regul Pept, PMID 21609736) — Single Selank injection altered expression of 34 inflammation-related genes in mouse spleen, including Bcl6 and its targets. Uchakina et al. 2008 (PMID 18577961) — Selank suppressed IL-6 gene expression and altered Th1/Th2 cytokine balance in patients with anxiety-asthenic disorders.

  • GABAergic system stabilization and neurotransmitter regulation

    Volkova et al. 2016 (Frontiers in Pharmacology, PMC4757669) — Selank altered expression of 45 of 77 neurotransmission-related genes in the rat frontal cortex within 1-3 hours, with a strong positive correlation with GABA effects (r = 0.86). The peptide influences GABA receptors, transporters, ion channels, dopamine receptors, and serotonin receptors. Kasian et al. 2017 (Behav Neurol, PMC5322660) — Selank enhanced diazepam's anxiolytic effects in chronic mild stress conditions, suggesting synergistic GABAergic modulation.

  • Stress resilience and anti-withdrawal effects

    Konstantinopolsky et al. 2022 (Bull Exp Biol Med, PMID 36322304) — A single Selank injection (0.3 mg/kg) reduced the total index of morphine withdrawal syndrome by 39.6%, significantly attenuated convulsive reactions, ptosis, and posture disorders, and increased tactile sensitivity thresholds ninefold. Efficacy approached that of diazepam (49.3% reduction at 2 mg/kg). Yasenyavskaya et al. 2021 — Selank exhibited stress-protective activity by modulating cytokine responses under chronic social stress.

  • Enkephalin system modulation and endogenous opioid regulation

    Zozulia et al. 2008 (PMID 18454096) — Patients had reduced leu-enkephalin half-life in serum, associated with illness characteristics. Selank increased this half-life measure, especially in GAD patients. Selank inhibits enzymes involved in enkephalin degradation, potentially amplifying endogenous analgesic and mood-regulating peptide signaling.

Key studies(8)

  1. Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB

    Zh Nevrol Psikhiatr Im S S Korsakova

    2008

    Landmark clinical trial demonstrating Selank's anxiolytic efficacy in GAD and neurasthenia. Anxiolytic effects were comparable to the benzodiazepine medazepam, but Selank additionally showed antiasthenic and psychostimulant effects without sedation, muscle relaxation, tolerance, or withdrawal. Patients had reduced leu-enkephalin half-life in serum at baseline; this measure increased during Selank treatment, particularly in GAD patients.

  2. Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic selank

    Clinical evaluation with EEG monitoring20 patients with GAD (ages 24-52)14 days, intranasal Selank 2700 mcg/day

    Syunyakov TS, Teleshova ES, Neznamov GG, Bochkarev VK

    European Psychiatry

    2012

    Identified two distinct response patterns: rapid responders (40%) showed abrupt symptom reduction within 1-3 days with HARS scores dropping from 20.3 to 7.0, while conventional responders (60%) achieved comparable improvement by day 14 (HARS 16.1 to 6.2). Rapid responders exhibited immediate EEG changes (increased beta-rhythm, decreased theta/alpha frequencies) after a single dose, suggesting pre-treatment neurophysiological characteristics may predict response trajectory.

  3. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders

    Comparative clinical studyPatients with anxiety-asthenic disorders (exact n not specified)14 days in vivo treatment

    Uchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA, Shcherbenko VE, Mezentseva MV, Gabaeva MV, Sokolov OIu, Zozulia AA, Ershov FI

    Zh Nevrol Psikhiatr Im S S Korsakova

    2008

    Selank at 10^-7 M completely suppressed IL-6 gene expression in peripheral blood of patients with depression while paradoxically increasing IL-6 concentration in cell cultures. Selank altered Th1/Th2 cytokine balance in patients with GAD and neurasthenia, with significant inverse correlation dependence in cytokine dynamics. Authors concluded Selank functions as a novel immunomodulator with potential adaptogenic benefits for elderly populations.

  4. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity

    Molecular pharmacology researchIn vitro receptor binding studiesN/A (mechanistic study)

    Vyunova TV, Andreeva LA, Shevchenko KV, Myasoedov NF

    Protein and Peptide Letters

    2018

    Demonstrated that Selank affects [3H]GABA binding as a positive allosteric modulator of GABA-A receptors. Selank can block the modulatory activity of diazepam and olanzapine, suggesting distinct but partially overlapping binding sites. Proposed that Selank's anxiolytic effects operate through subtype-selective, concentration-dependent allosteric modulation of GABA receptors, offering a mechanistic alternative to benzodiazepines with fewer adverse effects.

  5. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission

    Experimental pharmacology (preclinical)Rat frontal cortex tissue analysis1-3 hours post single injection

    Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P

    Frontiers in Pharmacology

    2016

    Selank rapidly and broadly altered neurotransmission-related gene expression: 45 of 77 genes changed at 1 hour (76% decreased), 22 genes changed at 3 hours (95% increased). Strong positive correlation with GABA effects at 1 hour (r = 0.86, p <= 0.05). Dramatic changes in hypocretin (Hcrt) expression: ~25-50 fold decrease at 1 hour, 128-fold increase by 3 hours. Confirms Selank's complex, time-dependent effects on GABAergic neurotransmission.

  6. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats

    Original research (preclinical)Outbred rats (ethanol-exposed and controls)30 weeks ethanol exposure; 7 days Selank treatment (0.3 mg/kg/day i.p.)

    Kolik LG, Nadorova AV, Antipova TA, Kruglov SV, Kudrin VS, Durnev AD

    Bulletin of Experimental Biology and Medicine

    2019

    Selank produced a cognitive-stimulating effect in unexposed 9-month-old rats and prevented formation of ethanol-induced memory and attention disturbances during alcohol withdrawal. Selank prevented ethanol-induced increase in BDNF content in the hippocampus and frontal cortex, confirming involvement of neurotrophin mechanisms in its neuroprotective effects. Relevant to age-related cognitive decline and substance-related neurodegeneration.

  7. The Influence of Selank on the Level of Cytokines Under the Conditions of 'Social' Stress

    Original research (preclinical)White nonlinear rats in 3 groups (intact, stressed, Selank-treated under stress)20 days social stress; Selank 100 mcg/kg/day

    Yasenyavskaya AL, Samotrueva MA, Tsibizova AA, Bashkina OA, Myasoedov NF, Andreeva LA

    Current Reviews in Clinical and Experimental Pharmacology

    2021

    Under chronic social stress, Selank significantly decreased concentrations of IL-1beta and IL-6, restored IL-4 levels, and suppressed TGF-beta1 and TNF-alpha production, reducing inflammatory markers toward control values. Demonstrates Selank's stress-protective activity through cytokine modulation, relevant to chronic stress-driven aging and inflammaging.

  8. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats

    Original research (preclinical)Outbred ratsSingle injection, 0.3 mg/kg i.p.

    Konstantinopolsky MA, Chernyakova IV, Kolik LG

    Bulletin of Experimental Biology and Medicine

    2022

    A single Selank injection reduced the total index of morphine withdrawal syndrome by 39.6%, significantly attenuated convulsive reactions, ptosis, and posture disorders, and increased tactile sensitivity thresholds ninefold vs controls. Efficacy approached that of diazepam (49.3% reduction at 2 mg/kg), demonstrating Selank's broad neuroregulatory potential without the addictive properties of benzodiazepines.

What research suggests over time

  • Weeks 2-4

    Russian clinical use

    Anxiolytic effect without sedation; reduced acute anxiety markers reported in Russian trials.

  • Months 2-3

    Russian observational

    Sustained anxiolysis and improved sleep reported by users; modulation of GABA/serotonin pathways.

  • Long-term

    Russian clinical use

    Used clinically in Russia for generalized anxiety. Limited Western data.

Regulation & availability

Why researchers look at it

A 62-patient trial showed anti-anxiety effects comparable to benzodiazepines — without the sedation, memory loss, or dependence. Also rapidly boosts BDNF, a key protein for brain cell growth. Registered in Russia since 2009; no established US compounding pathway or access date was identified.

Estimated cost
No approved product and no verified reference price
FDA status
Selank is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use (the 503A positive list or Category 1). FDA lists Selank acetate (TP-7) among bulk substances whose nominations were withdrawn and retains concerns about immunogenicity, aggregation, impurities, and inadequate safety information; withdrawal does not authorize compounding. Selank was not reviewed at the October or December 2024 PCAC meetings.
WADA status
Selank is not named on the 2026 WADA list. Its Russian therapeutic authorization means lack of FDA or EMA approval alone does not establish S0 prohibition. A definitive compound-specific classification was not verified; athletes should obtain a determination from their anti-doping organization. US compounding-category changes do not determine WADA status.
Prescribability
Selank is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use. FDA identifies Selank acetate as nominated but withdrawn, and Category 2 removal did not establish Category 1 eligibility. Selank is registered in Russia as 0.15% nasal drops for anxiety-related conditions and is available there without prescription. Ukrainian authorization was not verified.
Availability
Russia: registered since 2009 as 0.15% nasal drops for anxiety-related conditions and available without prescription. Ukrainian authorization was not verified. United States: not FDA-approved; no established 503A or 503B compounding pathway was identified. Selank was placed on the FDA Category 2 bulk drug substances list in late 2023 and removed from Category 2 on September 27, 2024; removal from Category 2 does not establish Category 1 eligibility or lawful prescription access. Europe and other markets: not approved as a medication. Pharmaceutical-grade Selank is difficult to obtain outside Russia, and most material available internationally is unregulated product of unvalidated purity.

International status

  • EU

    Not approved

  • US

    Selank is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use.

  • Russia

    Approved anxiolytic medication since 2009

Regulatory timeline(15)

  1. 1970s
    Tuftsin (Thr-Lys-Pro-Arg) identified as an immunostimulatory tetrapeptide fragment of IgG heavy chain Fc region by Victor Najjar at Tufts University.
  2. 1990s
    Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) designed and synthesized at the Institute of Molecular Genetics, Russian Academy of Sciences, in collaboration with the V.V. Zakusov Research Institute of Pharmacology. The Pro-Gly-Pro extension improves metabolic stability over native tuftsin.
  3. 2008
    Zozulia et al. publish landmark RCT in 62 GAD/neurasthenia patients demonstrating Selank's anxiolytic efficacy comparable to medazepam (PMID 18454096). Uchakina et al. publish immunomodulatory effects in anxiety patients (PMID 18577961).
  4. 2009
    Selank approved for human use by the Russian Federation Ministry of Health as a prescription anxiolytic (nasal spray, 0.15% solution) for generalized anxiety disorder. Made available in Russian and Ukrainian pharmacies.
  5. 2011
    Kolomin et al. publish Selank's effects on inflammation-related gene expression in mouse spleen (Regulatory Peptides, PMID 21609736).
  6. 2012
    Syunyakov et al. present clinical data on rapid vs slow responders in GAD at 20th European Congress of Psychiatry (European Psychiatry).
  7. 2014
    Kolomin et al. publish temporal dynamics of inflammation gene expression under Selank (Molecular Immunology, PMID 24291245).
  8. 2016
    Volkova et al. publish comprehensive GABAergic gene expression study in Frontiers in Pharmacology (PMC4757669), establishing molecular basis for Selank's anxiolytic mechanism.
  9. 2017
    Kasian et al. demonstrate Selank enhances diazepam's anxiolytic effect in chronic mild stress model (Behavioural Neurology, PMC5322660).
  10. 2018
    Vyunova et al. characterize Selank as a positive allosteric modulator of GABA-A receptors (Protein and Peptide Letters, PMID 30255741).
  11. 2019
    Kolik et al. demonstrate Selank's neuroprotective effects against ethanol-induced memory impairment via BDNF regulation (PMID 31625062).
  12. 2021
    Yasenyavskaya et al. demonstrate Selank's anti-inflammatory cytokine modulation under chronic social stress (PMID 32621722).
  13. 2022
    Konstantinopolsky et al. show Selank attenuates morphine withdrawal signs in rats (PMID 36322304).
  14. 2023-09
    FDA places Selank and 18 other peptide bulk drug substances on Category 2 interim list, effectively prohibiting compounding by 503A pharmacies in the United States.
  15. 2024-09-27
    FDA removes Selank acetate (TP-7) from Category 2; the nominator had intended to nominate a different substance. Selank was not among the substances reviewed at the October or December 2024 PCAC meetings.

Sources & FAQs

Research sources(14)

Frequently asked questions(5)

How does Selank compare to benzodiazepines for anxiety?

Clinical studies show Selank produces anxiolytic effects comparable to benzodiazepines like medazepam and phenazepam, but without the characteristic side effects of benzodiazepines: no sedation, no muscle relaxation, no amnesia, no tolerance development, and no withdrawal syndrome. Selank additionally provides antiasthenic and psychostimulant effects that benzodiazepines do not. Mechanistically, Selank acts as a positive allosteric modulator of GABA-A receptors at a distinct binding site from benzodiazepines. However, the clinical evidence comes from small Russian trials and has not been replicated internationally.

Is Selank safe for long-term use?

Long-term safety data for Selank is limited. Clinical trials have examined only short treatment periods, and the registered Russian product is labeled for short courses rather than continuous use. In the available studies, Selank showed a favorable safety profile with only mild, transient side effects (nasal irritation, occasional headache). Unlike benzodiazepines, no tolerance, dependence, or withdrawal has been documented. However, no human studies have examined continuous use beyond several weeks.

Can I get Selank in the United States?

Selank is not FDA-approved. FDA currently identifies Selank acetate as nominated but withdrawn, and it is not in Category 1 or on the positive 503A bulks list. Removal from Category 2 did not establish lawful compounding eligibility. No confirmed date for a US prescription-compounding pathway was identified.

What is the difference between Selank and Semax?

Both Selank and Semax are synthetic heptapeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and both are approved medications in Russia. However, they have different parent molecules and primary effects: Selank is derived from the immunopeptide tuftsin and is primarily an anxiolytic with immunomodulatory properties, while Semax is derived from ACTH(4-10) and is primarily a nootropic and neuroprotective agent. Selank's mechanism centers on GABAergic modulation and cytokine regulation, while Semax primarily enhances BDNF and NGF expression.

Does Selank have longevity or anti-aging benefits?

No direct lifespan extension studies have been conducted with Selank. However, Selank has several properties relevant to aging: (1) it elevates BDNF in the hippocampus, supporting neuroplasticity that declines with age; (2) it reduces pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha) that drive inflammaging; (3) it stabilizes GABAergic neurotransmission which deteriorates in aged brains; (4) it protects against stress-induced cognitive impairment, a major contributor to age-related cognitive decline; and (5) it inhibits enkephalin degradation, supporting endogenous pain and mood regulation. These properties position Selank as a neuroprotective candidate for healthy brain aging rather than a direct longevity agent.